AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32232781 — intervention group
Group type: COMPARATOR
Intervention: Usual precepting
Number of subjects: 100
Study 35742357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropocollagen gel treatment (group A, n = 47)
Number of subjects: 100
Study 35742357 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone (group B, n = 45)
Number of subjects: 100
Study 35742357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 100
Study 32214517 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 9
Study 32214517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 34491449 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebilda DC (RDC)
Number of subjects: 300
Study 34491449 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil DC Core (CDC)
Number of subjects: 300
Study 34491449 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicore Flow (MF)
Number of subjects: 300
Study 34491449 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall failure rate
Number of subjects: 300
Study 34491449 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger cavities (>3 surfaces)
Number of subjects: 300
Study 34491449 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment by dental students
Number of subjects: 300
Study 33218384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube first technique
Number of subjects: 16
Study 33218384 — intervention group
Group type: COMPARATOR
Intervention: Video laryngoscope technique
Number of subjects: 16
Study 34888663 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble corn fiber (SCF) 20 g/day for 2 months
Number of subjects: 20
Study 34888663 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 20
Study 33328324 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod 2 mg/d
Number of subjects: 1651
Study 33328324 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1651
Study 32909497 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily
Number of subjects: 250
Study 36429761 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended restart breaks (from 31 h to 55 h) after consecutive night shifts
Number of subjects: 30
Study 36429761 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard restart breaks)
Number of subjects: 30
Study 33922783 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine loading 40 mg/kg/day and maintenance 20 mg/kg/day
Number of subjects: 78
Study 33922783 — intervention group
Group type: COMPARATOR
Intervention: Caffeine loading 20 mg/kg/day and maintenance 10 mg/kg/day
Number of subjects: 78
Study 32985341 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 155 U every 12 weeks
Number of subjects: 282
Study 32985341 — intervention group
Group type: COMPARATOR
Intervention: Topiramate 50 to 100 mg/day
Number of subjects: 282
Study 32877791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-taught program (two-hour workshop and Body Safety Training workbook)
Number of subjects: 56
Study 32877791 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 56
Study 34783882 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-joint hybrid assistive limb (HAL-SJ)
Number of subjects: 34
Study 34783882 — intervention group
Group type: COMPARATOR
Intervention: Continuous passive motion (CPM)
Number of subjects: 34
Study 34183053 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV alternating with high-flow nasal oxygen
Number of subjects: 146
Study 34183053 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal oxygen alone
Number of subjects: 146
Study 34183053 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 146
Study 36205549 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (RW) consumption (250 mL/d, 5 d/wk for 3 weeks)
Number of subjects: 42
Study 36205549 — intervention group
Group type: COMPARATOR
Intervention: Alcohol abstention (for 3 weeks)
Number of subjects: 42
Study 34871046 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of ciprofloxacin
Number of subjects: 0
Study 34871046 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of trimethoprim-sulfamethoxazole
Number of subjects: 0
Study 34871046 — intervention group
Group type: COMPARATOR
Intervention: 14 days of antibiotic therapy
Number of subjects: 0
Study 35289895 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 0
Study 35289895 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 0
Study 33144086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 240
Study 33144086 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 32416996 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal benzodiazepine use
Number of subjects: 800
Study 32416996 — intervention group
Group type: COMPARATOR
Intervention: Restricted benzodiazepine use
Number of subjects: 800
Study 32416996 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative delirium assessment
Number of subjects: 800
Study 32416996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative awareness assessment
Number of subjects: 800
Study 34422166 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention using an audio-visual tool
Number of subjects: 138
Study 34422166 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 138
Study 32340155 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training intervention with lab-based tasks, specific dosage and duration not mentioned.
Number of subjects: 0
Study 34811957 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional neural network (CNN) model for auto-segmentation of clinical target volume (CTV)
Number of subjects: 155
Study 34811957 — intervention group
Group type: COMPARATOR
Intervention: AI model (CNN)
Number of subjects: 155
Study 34899426 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 60
Study 34899426 — intervention group
Group type: COMPARATOR
Intervention: Dialectical Behavior Therapy (DBT‐bt)
Number of subjects: 60
Study 35954975 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific psychoeducation about MBPs for mental health
Number of subjects: 188
Study 35954975 — intervention group
Group type: COMPARATOR
Intervention: General psychoeducation about psychological treatments for mental health
Number of subjects: 188
Study 35954975 — intervention group
Group type: EXPERIMENTAL
Intervention: Both specific and general psychoeducation
Number of subjects: 188
Study 34960005 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy (MNT)
Number of subjects: 48
Study 34960005 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard advice
Number of subjects: 48
Study 32147880 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide 1 (11-residue peptide tagged with rhodamine fluorophore)
Number of subjects: 0
Study 32147880 — intervention group
Group type: COMPARATOR
Intervention: Peptide 2 (randomized sequence of Peptide 1)
Number of subjects: 0
Study 32147880 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide 1
Number of subjects: 0
Study 36036731 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD group (n=15) consuming pecans (68 g) as part of a free-living diet
Number of subjects: 16
Study 36036731 — intervention group
Group type: EXPERIMENTAL
Intervention: SUB group (n=16) substituting pecans (68 g) for isocaloric foods from their habitual diet
Number of subjects: 16
Study 36036731 — intervention group
Group type: COMPARATOR
Intervention: Control group (nut-free, n=16)
Number of subjects: 16
Study 33794182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir with raltegravir
Number of subjects: 168
Study 33794182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir with tenofovir disoproxil fumarate and emtricitabine
Number of subjects: 168
Study 33794182 — intervention group
Group type: COMPARATOR
Intervention: After 2 years of ART (both regimens)
Number of subjects: 168
Study 35166174 — intervention group
Group type: EXPERIMENTAL
Intervention: Black PWH
Number of subjects: 40
Study 35166174 — intervention group
Group type: COMPARATOR
Intervention: White PWH
Number of subjects: 40
Study 34155899 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftobiprole
Number of subjects: 0
Study 34155899 — intervention group
Group type: COMPARATOR
Intervention: comparators
Number of subjects: 0
Study 35667721 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of anti-TB therapy
Number of subjects: 436
Study 35667721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis-specific dose anti-TB therapy
Number of subjects: 436
Study 35667721 — intervention group
Group type: COMPARATOR
Intervention: Standard of care antibacterials
Number of subjects: 436
Study 33588893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (1 g of ferric carboxymaltose) when hepcidin < 20 μg/l and intravenous iron and erythropoietin for 20 ≤ hepcidin < 41 μg/l.
Number of subjects: 399
Study 33588893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron treatment according to hepcidin levels.
Number of subjects: 399
Study 33588893 — intervention group
Group type: COMPARATOR
Intervention: Standard care (hepcidin quantification remained blinded).
Number of subjects: 399
Study 34059361 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-based education
Number of subjects: 98
Study 34059361 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 98
Study 34039329 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN)
Number of subjects: 0
Study 34039329 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Belief Network (DBN)
Number of subjects: 0
Study 34039329 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM)
Number of subjects: 0
Study 34039329 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Algorithm - Decision Tree (GA-DT)
Number of subjects: 0
Study 34039329 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-layer back propagation neural network (BPNN)
Number of subjects: 0
Study 34709668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon oil
Number of subjects: 59
Study 34709668 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-scented grapeseed oil
Number of subjects: 59
Study 34709668 — intervention group
Group type: COMPARATOR
Intervention: Pure deionized water
Number of subjects: 59
Study 34709668 — intervention group
Group type: COMPARATOR
Intervention: Particulate matter with HEPA filters
Number of subjects: 59
Study 32982226 — intervention group
Group type: EXPERIMENTAL
Intervention: TfR‐T12‐PEG‐PLA/PTX polymeric micelles (TfR‐T12‐PMs)
Number of subjects: 2
Study 32982226 — intervention group
Group type: COMPARATOR
Intervention: Unmodified PMs
Number of subjects: 2
Study 33509678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran with O-A time <8 h
Number of subjects: 535
Study 33509678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran with O-A time 8–24 h
Number of subjects: 535
Study 33509678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran with O-A time >24 h
Number of subjects: 535
Study 32026393 — intervention group
Group type: EXPERIMENTAL
Intervention: FFC (formoterol/fluticasone aerosol, pMDI)
Number of subjects: 15
Study 32026393 — intervention group
Group type: EXPERIMENTAL
Intervention: FBC (formoterol/budesonide dry powder inhaler, DPI)
Number of subjects: 15
Study 32026393 — intervention group
Group type: EXPERIMENTAL
Intervention: VFC (vilanterol/fluticasone furoate dry powder inhaler, DPI)
Number of subjects: 15
Study 33891907 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose anticoagulation with rivaroxaban 20 mg once daily (or full-dose heparin if oral administration is not feasible) for 30 days
Number of subjects: 600
Study 33891907 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with any approved venous thromboembolism prophylaxis regimen during hospitalization
Number of subjects: 600
Study 33891907 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban through 30 days
Number of subjects: 600
Study 33891907 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose anticoagulation with rivaroxaban or enoxaparin
Number of subjects: 600
Study 33302991 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 21
Study 33302991 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 21
Study 35156255 — intervention group
Group type: EXPERIMENTAL
Intervention: MB@QP-PDT
Number of subjects: 9
Study 35156255 — intervention group
Group type: EXPERIMENTAL
Intervention: MB-PDT
Number of subjects: 9
Study 35156255 — intervention group
Group type: COMPARATOR
Intervention: Control (NaOCl)
Number of subjects: 9
Study 35156255 — intervention group
Group type: COMPARATOR
Intervention: Er,Cr:YSGG laser
Number of subjects: 9
Study 34544560 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods-Motivational Interviewing approach with prerequisite orientations
Number of subjects: 800
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask wearing in the workplace
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask wearing in other public settings
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand sanitizing
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding social/meal gatherings
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding crowded places
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about COVID-19
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk of COVID-19
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived severity of COVID-19
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived effectiveness of individual preventive measures
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived effectiveness of organizational preventive measures
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived effectiveness of governmental preventive measures
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived preparedness for potential outbreak after work resumption
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to COVID-19 specific information through official media channels
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face communication regarding COVID-19
Number of subjects: 3035
Study 32924947 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of preventive measures implemented within workplace
Number of subjects: 3035
Study 36122608 — intervention group
Group type: EXPERIMENTAL
Intervention: IoT‐assisted TIGER
Number of subjects: 18
Study 36122608 — intervention group
Group type: COMPARATOR
Intervention: TSMT
Number of subjects: 18
Study 33038685 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback group, n = 11
Number of subjects: 23
Study 33038685 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 12
Number of subjects: 23
Study 33141770 — intervention group
Group type: EXPERIMENTAL
Intervention: No prophylactic antibiotic therapy
Number of subjects: 268
Study 32345383 — intervention group
Group type: EXPERIMENTAL
Intervention: New equation for estimating 24-h urinary Na excretion from casual spot urine specimen
Number of subjects: 807
Study 32345383 — intervention group
Group type: COMPARATOR
Intervention: INTERSALT method
Number of subjects: 807
Study 32345383 — intervention group
Group type: COMPARATOR
Intervention: Kawasaki method
Number of subjects: 807
Study 35320659 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of BNT162b2 vaccine
Number of subjects: 10125
Study 35320659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10125
Study 33468507 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy
Number of subjects: 108
Study 33468507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 34312662 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain plasticity-based computerized cognitive training programme
Number of subjects: 83
Study 34312662 — intervention group
Group type: COMPARATOR
Intervention: Active control (computer games)
Number of subjects: 83
Study 33230550 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV at birth, 6, and 10 weeks, bOPV+IPV at week 14, IPV at week 18
Number of subjects: 572
Study 33230550 — intervention group
Group type: COMPARATOR
Intervention: IPV at 6, 10, and 14 weeks, bOPV at 18 weeks
Number of subjects: 572
Study 33200489 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmetpantotenate (300 mg oral dose three times daily)
Number of subjects: 84
Study 33200489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 33200489 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmetpantotenate
Number of subjects: 84
Study 36206511 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexed to approximately 90°
Number of subjects: 32
Study 36206511 — intervention group
Group type: COMPARATOR
Intervention: Fully extended position (control)
Number of subjects: 32
Study 33228992 — intervention group
Group type: EXPERIMENTAL
Intervention: IDMQ J-aggregates
Number of subjects: 0
Study 33228992 — intervention group
Group type: COMPARATOR
Intervention: Free state IDMQ
Number of subjects: 0
Study 32887379 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoid (9 mg/day) for 6 weeks
Number of subjects: 40
Study 32887379 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 40
Study 32887379 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoid (9 mg/day) for 6 weeks in overweight subgroup
Number of subjects: 40
Study 32887379 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks in overweight subgroup
Number of subjects: 40
Study 32887379 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoid (9 mg/day)
Number of subjects: 40
Study 35751657 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin with concomitant strong CYP3A4 inhibitors
Number of subjects: 0
Study 35751657 — intervention group
Group type: COMPARATOR
Intervention: High midostaurin plasma exposure
Number of subjects: 0
Study 32389735 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (single dose preoperatively)
Number of subjects: 129
Study 32389735 — intervention group
Group type: COMPARATOR
Intervention: Control (acetaminophen and celecoxib alone)
Number of subjects: 129
Study 32772826 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg or 10 mg of melatonin
Number of subjects: 62
Study 35441908 — intervention group
Group type: EXPERIMENTAL
Intervention: Secret Agent Society (SAS)
Number of subjects: 89
Study 35441908 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 89
Study 33637368 — intervention group
Group type: EXPERIMENTAL
Intervention: Test/motivational interviewing group
Number of subjects: 174
Study 33637368 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 174
Study 32020185 — intervention group
Group type: EXPERIMENTAL
Intervention: ISG15 secreted from HT29 cells and primary 3D colonoids through JAK1-pSTAT-IRF9-dependent and independent pathways.
Number of subjects: 0
Study 32020185 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR3 and TNF treatment of human IECs.
Number of subjects: 0
Study 32020185 — intervention group
Group type: EXPERIMENTAL
Intervention: Human peripheral blood mononuclear cells (PBMCs) treated with ISG15.
Number of subjects: 0
Study 35060609 — intervention group
Group type: EXPERIMENTAL
Intervention: UMC+CC (Usual Medical Care plus Chiropractic Care)
Number of subjects: 750
Study 35060609 — intervention group
Group type: COMPARATOR
Intervention: UMC (Usual Medical Care)
Number of subjects: 750
Study 35060609 — intervention group
Group type: EXPERIMENTAL
Intervention: UMC+CC
Number of subjects: 750
Study 35060609 — intervention group
Group type: COMPARATOR
Intervention: UMC
Number of subjects: 750
Study 34085117 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position PCNL
Number of subjects: 200
Study 34085117 — intervention group
Group type: COMPARATOR
Intervention: Flank position PCNL
Number of subjects: 200
Study 34605384 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group
Number of subjects: 75
Study 34605384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietician-led support group
Number of subjects: 75
Study 34605384 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal support group
Number of subjects: 75
Study 34605384 — intervention group
Group type: COMPARATOR
Intervention: All participants
Number of subjects: 75
Study 32219719 — intervention group
Group type: EXPERIMENTAL
Intervention: C. albicans from HVS samples
Number of subjects: 228
Study 32219719 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 randomly selected resistant isolates
Number of subjects: 228
Study 32219719 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolate RPCA9
Number of subjects: 228
Study 32219719 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolate RPCA61
Number of subjects: 228
Study 32219719 — intervention group
Group type: EXPERIMENTAL
Intervention: HVS isolates RPCA 21, RPCA 22, and RPCA 44
Number of subjects: 228
Study 33310502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (monotherapy with selective serotonin reuptake inhibitors, SSRI, or selective serotonin noradrenalin reuptake inhibitors, SSNRI)
Number of subjects: 38
Study 33310502 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy (interpersonal psychotherapy)
Number of subjects: 38
Study 32899492 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine intervention (250 mL of wine/day, 4 weeks)
Number of subjects: 11